Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
676 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peritoneal Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2016', provides an overview of the Peritoneal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects - The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Peritoneal Cancer Overview 7 Therapeutics Development 8 Peritoneal Cancer - Therapeutics under Development by Companies 10 Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Peritoneal Cancer - Pipeline Products Glance 18 Peritoneal Cancer - Products under Development by Companies 22 Peritoneal Cancer - Products under Investigation by Universities/Institutes 29 Peritoneal Cancer - Companies Involved in Therapeutics Development 30 Peritoneal Cancer - Therapeutics Assessment 111 Drug Profiles 137 Peritoneal Cancer - Dormant Projects 651 Peritoneal Cancer - Discontinued Products 656 Peritoneal Cancer - Product Development Milestones 657 Appendix 662
List of Tables
Number of Products under Development for Peritoneal Cancer, H2 2016 21 Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2016 22 Number of Products under Development by Companies, H2 2016 24 Number of Products under Development by Companies, H2 2016 (Contd..1) 25 Number of Products under Development by Companies, H2 2016 (Contd..2) 26 Number of Products under Development by Companies, H2 2016 (Contd..3) 27 Number of Products under Development by Companies, H2 2016 (Contd..4) 28 Number of Products under Development by Companies, H2 2016 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2016 30 Comparative Analysis by Late Stage Development, H2 2016 31 Comparative Analysis by Clinical Stage Development, H2 2016 32 Comparative Analysis by Early Stage Development, H2 2016 33 Comparative Analysis by Unknown Stage Development, H2 2016 34 Products under Development by Companies, H2 2016 35 Products under Development by Companies, H2 2016 (Contd..1) 36 Products under Development by Companies, H2 2016 (Contd..2) 37 Products under Development by Companies, H2 2016 (Contd..3) 38 Products under Development by Companies, H2 2016 (Contd..4) 39 Products under Development by Companies, H2 2016 (Contd..5) 40 Products under Development by Companies, H2 2016 (Contd..6) 41 Products under Investigation by Universities/Institutes, H2 2016 42 Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2016 43 Peritoneal Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 44 Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 45 Peritoneal Cancer - Pipeline by Aduro BioTech, Inc., H2 2016 46 Peritoneal Cancer - Pipeline by Advanced Accelerator Applications S.A., H2 2016 47 Peritoneal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 48 Peritoneal Cancer - Pipeline by Amgen Inc., H2 2016 49 Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 50 Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2016 51 Peritoneal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 52 Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 53 Peritoneal Cancer - Pipeline by Bayer AG, H2 2016 54 Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 55 Peritoneal Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 56 Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 57 Peritoneal Cancer - Pipeline by Celsion Corporation, H2 2016 58 Peritoneal Cancer - Pipeline by CerRx, Inc., H2 2016 59 Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 60 Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2016 61 Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016 62 Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2016 63 Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H2 2016 64 Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 65 Peritoneal Cancer - Pipeline by EirGenix Inc., H2 2016 66 Peritoneal Cancer - Pipeline by Eisai Co., Ltd., H2 2016 67 Peritoneal Cancer - Pipeline by Eli Lilly and Company, H2 2016 68 Peritoneal Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 69 Peritoneal Cancer - Pipeline by Exelixis, Inc., H2 2016 70 Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 71 Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 72 Peritoneal Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 73 Peritoneal Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016 74 Peritoneal Cancer - Pipeline by Genelux Corporation, H2 2016 75 Peritoneal Cancer - Pipeline by Genentech, Inc., H2 2016 76 Peritoneal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2016 77 Peritoneal Cancer - Pipeline by Glycotope GmbH, H2 2016 78 Peritoneal Cancer - Pipeline by Gradalis Inc., H2 2016 79 Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2016 80 Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2016 81 Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H2 2016 82 Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2016 83 Peritoneal Cancer - Pipeline by Innate Pharma S.A., H2 2016 84 Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2016 85 Peritoneal Cancer - Pipeline by Juno Therapeutics Inc., H2 2016 86 Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 87 Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 88 Peritoneal Cancer - Pipeline by Mabion SA, H2 2016 89 Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 90 Peritoneal Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016 91 Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2016 92 Peritoneal Cancer - Pipeline by Medivation, Inc., H2 2016 93 Peritoneal Cancer - Pipeline by Merck & Co., Inc., H2 2016 94 Peritoneal Cancer - Pipeline by Merck KGaA, H2 2016 95 Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 96 Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 97 Peritoneal Cancer - Pipeline by MolMed S.p.A., H2 2016 98 Peritoneal Cancer - Pipeline by Mycenax Biotech Inc., H2 2016 99 Peritoneal Cancer - Pipeline by Neopharm Ltd., H2 2016 100 Peritoneal Cancer - Pipeline by Novartis AG, H2 2016 101 Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H2 2016 102 Peritoneal Cancer - Pipeline by Oncobiologics, Inc., H2 2016 103 Peritoneal Cancer - Pipeline by Oncolix, Inc., H2 2016 104 Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 105 Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 106 Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 107 Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2 2016 108 Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2016 109 Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016 110 Peritoneal Cancer - Pipeline by Quest PharmaTech Inc., H2 2016 111 Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 112 Peritoneal Cancer - Pipeline by Samyang Holdings Corporation, H2 2016 113 Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2016 114 Peritoneal Cancer - Pipeline by Sotio a.s., H2 2016 115 Peritoneal Cancer - Pipeline by TapImmune Inc., H2 2016 116 Peritoneal Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 117 Peritoneal Cancer - Pipeline by Tesaro, Inc., H2 2016 118 Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016 119 Peritoneal Cancer - Pipeline by Tyrogenex, Inc., H2 2016 120 Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016 121 Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 122 Peritoneal Cancer - Pipeline by Vyriad, H2 2016 123 Assessment by Monotherapy Products, H2 2016 124 Number of Products by Stage and Target, H2 2016 126 Number of Products by Stage and Mechanism of Action, H2 2016 136 Number of Products by Stage and Route of Administration, H2 2016 147 Number of Products by Stage and Molecule Type, H2 2016 149 Peritoneal Cancer - Dormant Projects, H2 2016 664 Peritoneal Cancer - Dormant Projects (Contd..1), H2 2016 665 Peritoneal Cancer - Dormant Projects (Contd..2), H2 2016 666 Peritoneal Cancer - Dormant Projects (Contd..3), H2 2016 667 Peritoneal Cancer - Dormant Projects (Contd..4), H2 2016 668 Peritoneal Cancer - Discontinued Products, H2 2016 669
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.